Format

Send to

Choose Destination
J Gastrointest Oncol. 2018 Jun;9(3):517-526. doi: 10.21037/jgo.2018.03.05.

Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma.

Author information

1
Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
2
Department of Liver Failure Treatment and Research Center, Beijing 302 Hospital, Beijing 100039, China.
3
Cancer Registry, Yale New Haven Hospital, New Haven, CT, USA.
4
Department of Surgery, Section of Surgical Oncology, Yale University School of Medicine, New Haven, CT, USA.
5
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
6
Department of Surgery, Section of Thoracic Surgery, Yale University School of Medicine, New Haven, CT, USA.
7
Department of Environmental Health Sciences, Yale University School of Public Health, New Haven, CT, USA.

Abstract

Background:

Adjuvant therapy for gastric adenocarcinoma has shown a survival advantage, though it may be underutilized. The purpose of this study is to examine how infrequently adjuvant therapy is administered with curative intent gastrectomy for node positive gastric cancer and the long-term effects to patients.

Methods:

The National Cancer Database was queried from 2006-2013 for patients with node positive gastric adenocarcinoma undergoing a potentially curative gastrectomy. Overall survival was compared between patients who received adjuvant chemotherapy or chemoradiation and those who did not.

Results:

Of 2,565 patients, 793 (30.9%) patients did not receive any adjuvant chemotherapy or radiation therapy, while 147 (5.7%) received peri-operative chemotherapy and 723 (28.2%) received post-operative chemoradiation. From 2006-2013, the percentage of patients receiving peri-operative chemotherapy rose from 1.1% to 9.9%, while those receiving post-operative chemoradiation decreased from 39.7% to 21.6%. The adjusted restricted mean survival time over 5 years for no adjuvant therapy was 27.7 months, peri-operative chemotherapy was 39.6 months, and post-operative chemoradiation was 37.7 months (P<0.0001).

Conclusions:

Approximately one third of patients treated for node positive gastric cancer undergo surgical resection without adjuvant therapy. This is associated with poorer survival, highlighting the need for improvement in multimodality care and cancer outcomes.

KEYWORDS:

Gastric cancer; adenocarcinoma; adjuvant therapy; survival

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center